- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00551850
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors
The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors. AV-412 is a novel inhibitor of the EGFR-tyrosine kinase, with added activity against Her2 and other oncogenic kinases. Based on evidence of preclinical activity in various solid tumors, AV-412 is being developed as a possible novel treatment for cancer in humans.
PURPOSE: The purpose of this study is to test the safety and tolerability of AV-412, and determine the maximum tolerated dose of AV-412 when administered orally three times weekly.
Study Overview
Detailed Description
This is an open-label, dose escalation trial, and all subjects will receive oral AV-412 administered three times weekly or once weekly for 4 weeks (1 cycle) to evaluate safety and tolerability of AV-412. Treatment duration will be a minimum of 2 consecutive dosing cycles (8 weeks), if tolerated.
- Upon completion of the 2 cycles, subjects with documented stable disease or an objective response may continue to receive therapy at the same dose and schedule previously utilized, as long as tolerability is acceptable, for up to 1 year. Treatment beyond 1 year from the time of enrollment will be reviewed on a case-by-case basis between the sponsor and investigator.
- Subjects experiencing unacceptable toxicities or with documented disease progression will be discontinued from further participation in the study Accrual to next cohort will occur only after acceptable tolerance has been demonstrated throughout Cycle 1, and only after consultation with medical monitor.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Hospital
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Kansas Masonic Cancer Research Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
New York
-
New York City, New York, United States, 10461
- Montefiore Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to give written informed consent
- 18 years and older
- Evaluable disease or measurable disease according to RECIST.
Subjects enrolled in the MTD Cohort B must have the following:
- A diagnosis of non-small cell lung carcinoma (NSCLC)
- Received prior therapy with erlotinib or gefitinib for a minimum of 12 weeks
- Demonstrated disease stabilization or an objective response during that prior treatment
- Evidence of disease progression and measurable disease, according to RECIST
- Histologically confirmed solid tumor malignancy that is locally advanced or metastatic
- Disease that is currently refractory to, or not amenable to, standard therapy and/or subjects who are unwilling to try standard chemotherapy
- Disease that is currently not amenable to surgical intervention, due to either medical contraindications or non-resectability of the tumor
- Karnofsky performance status ≥ 70%
- Life expectancy ≥ 3 months, as judged by the investigator
- No childbearing potential; or use of a medically acceptable form of contraception during the study through the end of follow-up period
Exclusion Criteria:
- Pregnant or lactating women
- Primary CNS malignancy and/or active CNS metastases (or leptomeningeal disease) not controlled by prior surgery or radiotherapy
- Hematologic malignancies (including leukemia of any form, lymphoma, and multiple myeloma)
Active second malignancy or history of another malignancy within 2 years with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (CIS) of the breast or cervix
- Controlled, superficial carcinoma of the bladder
- T1a or b prostate carcinoma comprising < 5% of resected tissue, with prostate specific antigen (PSA) within normal limits (WNL) since resection
Any of the following hematologic abnormalities:
- Hemoglobin ≤ 9.0 g/dL
- ANC ≤ 1500 per mm3
- Platelet count ≤ 75,000 per mm3
Any of the following serum chemistry abnormalities:
- Total bilirubin > 1.5 × the ULN
- AST or ALT ≥ 3 × ULN (≥ 5 × ULN if due to hepatic involvement by tumor)
- Serum albumin < 2.5 g/dL
- Creatinine ≥ 1.5 × ULN
Significant cardiovascular disease or condition, including:
- Congestive heart failure requiring therapy
- Ventricular arrhythmia requiring therapy
- Severe conduction disturbance (including QTc interval prolongation > 0.47 sec [corrected], history of a severe arrhythmia, or history of a familial arrhythmia [eg, Wolff-Parkinson-White syndrome])
- Angina pectoris requiring therapy
- Left ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogram
- Uncontrolled hypertension (as determined by investigator)
- Myocardial infarction (MI) within 6 months prior to administration of first dose
- >Class I cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria
Significant gastrointestinal abnormalities, including:
- Requirement for IV alimentation
- Prior surgical procedures affecting absorption
Active peptic ulcer disease
- Grade 2 diarrhea due to any etiology
- Ulcerative colitis or Crohn's disease
Known history of significant ophthalmologic abnormalities, including:
- Severe dry eye syndrome
- Keratoconjunctivitis sicca
- Sjogren's syndrome
- Severe exposure keratopathy
- Disorders that might increase the risk for epithelium-related complications (eg, bullous keratopathy, aniridia, severe chemical burns, neutrophilic keratitis)
- Serious/active infection or any infection requiring parenteral antibiotics
- Inadequate recovery from prior antineoplastic therapy
- Inadequate recovery from any prior surgical procedure or major surgical procedure within 2 weeks prior to administration of first dose
- Life-threatening illness, or organ system dysfunction which, in the opinion of the investigator, would limit life expectancy to < 3 months, compromise the subject's safety, or interfere with evaluation of the safety of the study drug
- Psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary study procedures
- Inability to comply with the protocol requirements
Drugs and Treatments to be Excluded:
Any prior therapy with the following:
- Doxorubicin at a cumulative dose > 450 mg/m2 or equivalent dose of another anthracycline (eg, daunorubicin, epirubicin, idarubicin) or anthracenedione (eg, mitoxantrone).
- HKI-272 or any other irreversible EGFR tyrosine kinase inhibitor (eg, CI- 1033 and similar agents).
Therapy within 2 weeks prior to administration of the first dose or at any time during the study with:
• Herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components)
Therapy within 3 weeks prior to administration of the first dose or at any time during the study with:
- Erlotinib (Tarceva®) or gefitinib (Iressa®)
- Antibodies to EGFR (eg, cetuximab, panitumumab)
- Agents targeting HER2 (ErbB2) (eg, trastuzumab, lapatinib)
Therapy within 4 weeks prior to administration of the first dose or at any time during the study with:
- Chemotherapy with the exception of the following:
- Mitomycin C or nitrosoureas within 6 weeks prior to administration of first dose
- High-dose chemotherapy with stem cell support within 6 months prior to administration of first dose
- Other antineoplastic agents (standard or therapeutic) for primary malignancy, including but not limited to signal transduction inhibitors and monoclonal antibodies.
- Immunotherapy, cancer vaccines, biological response modifiers
Systemic hormonal therapy within 4 weeks prior to administration of the first dose or at any time during the study, with the exception of the following allowed therapies:
- Hormonal therapy for appetite stimulation or contraception
- Nasal, ophthalmic, and topical glucocorticoid preparations
- Oral replacement therapy for adrenal insufficiency
- Stable hormonal therapy for prostate carcinoma
- Low-dose maintenance, or short course (ie, 7 days) steroid therapy for other conditions
- Any experimental therapy within 4 weeks prior to or at any time during the study
Radiotherapy for the primary malignancy:
- Within 2 weeks prior to first study drug administration if involving ≤25% of marrow-containing bone
- Within 4 weeks prior to first study drug administration if involving >25% of marrow-containing bone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of AV-412 administered orally 3 times weekly and once weekly in subjects with relapsed or refractory solid tumor malignancies.
Time Frame: 4 weeks (1 cycle)
|
4 weeks (1 cycle)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterize the pharmacokinetic (PK) profile of AV-412
Time Frame: 8 weeks ( 2 cycles)
|
8 weeks ( 2 cycles)
|
Determine the effect of AV-412 on global and targeted gene expression patterns in blood from all subjects enrolled in the MTD expansion cohorts
Time Frame: 8 weeks (2 cycles)
|
8 weeks (2 cycles)
|
Evaluate the antineoplastic activity of AV-412
Time Frame: 8 weeks (2 cycles)
|
8 weeks (2 cycles)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pankaj Bhargava, M.D., AVEO Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AV-412-07-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Bristol-Myers SquibbRecruitingAdvanced CancerUnited States, Spain, Belgium, Argentina, Korea, Republic of, Japan
-
HaEmek Medical Center, IsraelNot yet recruiting
Clinical Trials on AV-412
-
AVEO Pharmaceuticals, Inc.TerminatedSafety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor MalignanciesTumorUnited States, Argentina
-
University Hospital, Gentofte, CopenhagenRigshospitalet, Denmark; Lund University HospitalUnknownHeart Failure | Ischemic CardiomyopathyDenmark, Sweden
-
Northwestern UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia With Suspected Alzheimer's DiseaseUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Vasomune Therapeutics, Inc.RecruitingPneumonia, Viral | Pneumonia | Acute Respiratory Distress Syndrome | Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | Viral or Bacterial InfectionsUnited States
-
Heart and Diabetes Center North-Rhine WestfaliaCompletedAtrial Fibrillation | AV Node Ablation | Escape; RhythmGermany
-
University of California, San DiegoCompletedAtrioventricular Block | Cardiac Arrhythmia | Sick Sinus Syndrome | Symptomatic BradycardiaUnited States
-
Military Institute of Medicine, PolandUnknown
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States